Tag Archives: past

  • Waste Removal

    … to work. A tool like a Pareto curve will also help to identify how important it is to remove various materials or components from your work. Of course with modern technology, researchers can readily identify many components of their methodologies more easily than in the past, which is another important aspect to remember in lean biomanufacturing. …

  • Pharmaceutical Consultants-The Key to a Rapidly Changing Industry

    … margins, imminent novel healthcare reforms and increasingly heavy-handed government intervention, rapid technological advances and a growing number of combination products—all these are happening now or are on the horizon. As a result, the role of pharmaceutical consultants is both expanding in scope, as well as narrowing in response to needed specialization. According to Peakman, in the past pharmaceutical companies mostly used general consultants for large business-wide endeavors like …

  • Lean Manufacturing Implementation: Successfully Overcoming Obstacles

    The current economic climate, combined with increasing regulations has placed pharmaceutical manufacturers in the difficult position of having to reduce waste, improve processes, and increase productivity. Although lean manufacturing can absolutely be the answer, some companies have found lean manufacturing implementation to be an uphill battle. That is not to say, however, that there have not been some dramatic success stories.

  • Lean Manufacturing: What it means to the Pharmaceutical Industry

    Over the past decade or so, the pharmaceutical industry has sporadically attempted to embrace lean manufacturing. While a manufacturing philosophy that aims to reduce waste and boost productivity would certainly appear to be a good partner for this industry, so far the results have been less that optimum. This does not have to be the case, however.

  • How to Do a SWOT Analysis as Part of a Business Plan or Business Process Strategy

    … that are unique to the company, product or division in question.  Some examples of strengths would be having a key scientist on your team that has a unique skill set or knowledge that will make your new product a success.  Other strength examples include patents, knowledge of a particular niche area, and manufacturing advances that allow you to create something that was not readily available in the past. Weaknesses are just the opposite – some examples include lack of a patent or relying on …

  • Influenza of the Future

    … to advance viral biology in such a way that pandemic outbreaks like these could be things of the past.  Scientists today are developing wide ranging viral technology that could help increase infection response vaccinations, if a large event were to break out.  Scientists hope in the next 20 years to have enough viral technology that in the case of any large viral outbreak, they would be ready for it.  But is this even a possibility concerning the wide variety of diseases and viruses that …

  • FTC Commissioner Rosch Will Speak at ACI’s Pharmaceutical Antitrust Forum

    FTC Commissioner J. Thomas Rosch will speak about the three main areas of antitrust concern for pharma manufacturers, at ACI’s 5th Annual In-House Counsel Forum on Pharmaceutical Antitrust, to take place at the Helmsley Park Lane Hotel in New York City on February 17th and 18th, 2010. The three areas he will cover are: –    Reverse settlement payments –    Authorized genetics –    Pharmaceutical mergers In past months, a consensus position by DOJ and the FTC has been …

  • The Future of Influenza Vaccine Design

    The impact of influenza can only be reduced through a vaccine.  Today, the U.S. has only approved the use of inactivated influenza virus vaccines, and to be effective, these have to contain an H1N1, and H3N2, and a B virus component.  In the past, at least one of these components had to be modified due to antigenic drift of the strain circulating the human population. Vaccines are prepared by growing viral strains in embryonated eggs, and then the virus is purified and turned noninfectious …

  • AAI, CONSUMER GROUPS ENCOURAGE CONGRESS TO BAN PATENT SETTLEMENTS AND RESTORE COMPETITION IN MARKET FOR GENERIC DRUGS

    … payments in pharmaceutical patent settlements in the final health reform legislation that both the House and Senate will consider soon. During the past decade, some branded and generic pharmaceutical firms have entered into settlements in which the branded firm pays the generic firm not to enter the market.  These arrangements, known as exclusion payments or pay-for-delay settlements, can significantly impede the entry of generic drugs.  The Federal Trade Commission estimates that these …

  • Pharmaceutical Marketing Strategies towards Physicians Are Not Trusted

    … consultancies, membership to advisory boards, and stock holding.  Extravagant gifts and travel aid have been the center of attention in the past; however, these have been inhibited by the industry and professional codes.  Now we are seeing that regular, more modest, sponsored events may become more influential, and the main point of contact between pharma and doctors. The Australian information is quite difficult to access.  Summary reports listing each function should be easily accessible to …

  • Building Value in a Biotech Company Through Partnerships

    … that have complementary capabilities.  Although this seems logical and feasible, since both have similar cultures and complementary skills working together on a common purpose, these partnerships have failed in the past. What happens is that the partnership relationship works well great until the companies have to commit to additional resources to take an initial lead to a drug candidate, and they start discussions to partner with pharma companies.  Then, they start thinking what’s best: to …

  • Emerging Trends in the Pharmaceutical Industry

    As the Global economy continues to deteriorate in many parts of the world, the same can’t be said about the booming pharmaceutical industry.  According to researchandmarkets.com the global pharmaceutical market is expected to earn well over one trillion dollars in revenues by the end of 2011.  This forecast is based on many growing trends, which seem to not be affected by the global economic crisis of the past few years.  Some of these trends include the growth of developing pharmaceutical …